The FDA recently released its draft guidance outlining its recommended best practices for trademark name development. The guidance is titled, “Best Practices in Developing Proprietary Names for Drugs” and can found http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM398997.pdf  

The industry will have a period of 60 days to submit comments to the docket. It is expected that a number of interested parties will submit comments in the coming weeks reflecting their recommendations for improvement to the new guidance. 

If you have any questions on trademark related matters, please contact Terrence J. McAllister on (203) 327 4500 x135 or email at tmcallister@ogrp.com or Jeff Scepanski at jscepanski@ogrp.com.